表紙
市場調査レポート

原発性全身性アミロイドーシス :世界の治験レビュー

Primary Systemic Amyloidosis Global Clinical Trials Review, H1, 2014

発行 GlobalData 商品コード 305094
出版日 ページ情報 英文 95 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
原発性全身性アミロイドーシス :世界の治験レビュー Primary Systemic Amyloidosis Global Clinical Trials Review, H1, 2014
出版日: 2014年05月30日 ページ情報: 英文 95 Pages
概要

当レポートでは、原発性全身性アミロイドーシスに関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主な先進国・新興国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤などの情報を盛り込んで、概略以下の構成でお届けします。

目次

イントロダクション

  • 原発性全身性アミロイドーシス
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の上位国
    • 欧州の上位5ヶ国
    • 北米の主要国

G7諸国での治験件数:代謝性疾患の治験全体における原発性全身性アミロイドーシスの割合

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:代謝性疾患の治験全体における原発性全身性アミロイドーシスの割合

E7諸国での治験件数:進捗状況別

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

  • 原発性全身性アミロイドーシス治療薬の治験に参加している上位企業

有望な薬剤

治験のプロファイル

  • 代表的企業の治験の概要
    • Prothena Corporation plc
    • Onclave Therapeutics Limited
  • 代表的な研究機関・病院の治験の概要
    • National Cancer Institute
    • Boston Medical Center
    • Mayo Clinic
    • The University of Texas M. D. Anderson Cancer Center
    • Eastern Cooperative Oncology Group
    • Nanjing University
    • Fred Hutchinson Cancer Research Center
    • The Cleveland Clinic
    • University Hospital, Limoges
    • Children's Oncology Group

5つの代表的な治験のプロファイル

付録

図表一覧

目次
Product Code: GDHC2177CTIDB

GlobalData's clinical trial report, "Primary Systemic Amyloidosis Global Clinical Trials Review, H1, 2014" provides data on the Primary Systemic Amyloidosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Primary Systemic Amyloidosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Primary Systemic Amyloidosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Primary Systemic Amyloidosis
    • Report Guidance
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
    • Top Countries Contributing to Clinical Trials in Asia-Pacific
    • Top Five Countries Contributing to Clinical Trials in Europe
    • Top Countries Contributing to Clinical Trials in North America
  • Clinical Trials by G7 Countries: Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Primary Systemic Amyloidosis
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Primary Systemic Amyloidosis Therapeutics Clinical Trials
  • Prominent Drugs
    • Clinical Trial Profiles
      • Clinical Trial Overview of Top Companies
      • Prothena Corporation plc
      • Clinical Trial Overview of Prothena Corporation plc
      • Onclave Therapeutics Limited
      • Clinical Trial Overview of Onclave Therapeutics Limited
    • Clinical Trial Overview of Top Institutes / Government
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • Boston Medical Center
      • Clinical Trial Overview of Boston Medical Center
      • Mayo Clinic
      • Clinical Trial Overview of Mayo Clinic
      • The University of Texas M. D. Anderson Cancer Center
      • Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center
      • Eastern Cooperative Oncology Group
      • Clinical Trial Overview of Eastern Cooperative Oncology Group
      • Nanjing University
      • Clinical Trial Overview of Nanjing University
      • Fred Hutchinson Cancer Research Center
      • Clinical Trial Overview of Fred Hutchinson Cancer Research Center
      • The Cleveland Clinic
      • Clinical Trial Overview of The Cleveland Clinic
      • University Hospital, Limoges
      • Clinical Trial Overview of University Hospital, Limoges
      • Children's Oncology Group
      • Clinical Trial Overview of Children's Oncology Group
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Region, 2014*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014*
  • Primary Systemic Amyloidosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Primary Systemic Amyloidosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014*
  • Primary Systemic Amyloidosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Primary Systemic Amyloidosis Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Primary Systemic Amyloidosis Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Primary Systemic Amyloidosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Prothena Corporation plc, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Onclave Therapeutics Limited, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Boston Medical Center, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Eastern Cooperative Oncology Group, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Nanjing University, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials Market, Global, Clinical Trials by The Cleveland Clinic, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital, Limoges, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2014*

List of Figures

  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014*
  • Primary Systemic Amyloidosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Primary Systemic Amyloidosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014*
  • Primary Systemic Amyloidosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Primary Systemic Amyloidosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top